biOasis Announces the Successful Delivery to the CNS of an Enzyme used to Treat Hunter Syndrome

Vancouver, BC–(Business Wire)– biOasis Technologies, Inc. (OTCQX:BIOAF; TSX.V:BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), announces the completion and assessment of the data in the knockout mouse model of Hunter Syndrome (MPS II) performed in Padova, Italy, by a team led by Dr. Maurizio Scarpa of the Brains for Brain Foundation.

This knockout mouse model of Hunter Syndrome (MPS II) showed that the Transcend fusion protein, MTfp-I2S (MTfp-Iduronate-2-sulfatase), was able to cross the blood-brain barrier, reached therapeutic levels in the CNS and significantly decreased the number of lysosomal storage vacuoles in the cytoplasm of brain cells.

The study also showed that MTfp-I2S normalizes the GAG level in the periphery (liver & urine) showing that the recombinant enzyme is active and distributed throughout the body. The MTfp-I2S treatments were safe, showing no toxicity, and the activity of the enzyme was not affected by the MTfp peptide carrier.

Sufferers of the Lysosomal Storage Disease, Mucopolysaccharidoses Type II (MPS II or Hunter Syndrome), are unable to produce sufficient quantities of the enzyme Iduronate-2-sulfatase (I2S), resulting in the impaired degradation and removal of glycosaminoglycans (GAGs) from the body. The resulting accumulation of lysosomal storage vacuoles in cells leads to the death of these cells, causing severe physical and mental impairments.

Dr. Maurizio Scarpa, President of the Brains for Brain Foundation stated, “The study that we have recently performed in collaboration with biOasis produced some exciting data. I am very encouraged that after some adjustments regarding dosing, we might be able to move this program into the clinic. My goal and I am sure the goal of biOasis as well, is to help children with this devastating disease. I am very encouraged that based on these results, Transcend may play an important role in helping us achieve our goals.”

CEO Rob Hutchison commented, “It has been a pleasure working with Dr. Scarpa and the Brains for Brain foundation. When we looked to advance our Lysosomal Storage Disease program, Dr. Scarpa along with Dr. Begley where our first choices and we were very pleased when, through their foundation, Brains for Brain, they agreed to work with us. Working with these world leaders and their team at the University of Padova has been very exciting for us. The data that they have generated has provided biOasis with confirmation that we’ve been on the right track with our Transcend peptide carrier and we are now poised to potentially help make a difference to children coping with this awful disease.”

About The Brains for Brain Foundation

Mission: B4B aims to develop new and innovative therapeutic strategies to cross the Blood-Brain Barrier, a capillary system that shields and defends the CNS from circulating neurotoxins. It has a very important filtering protective function but unfortunately also prevents access to the brain by most candidate therapeutic drugs under development for CNS diseases. ? The B4B mission consists of the promotion of an International Network of health professionals in rare disorders, specifically in the field of rare neurological pediatric diseases. The purposes of the FOUNDATION are to support the following activities in the field of rare Neurological Disorders: – scientific research – knowledge dissemination – social and socio-medical assistance – health assistance.

About biOasis

biOasis Technologies Inc. is a biopharmaceutical company headquartered in Richmond, Canada focused on overcoming the limitations of therapeutic drug delivery across the BBB. The company is developing and commercializing a proprietary brain delivery technology to address unmet medical needs in the treatment of central nervous system disorders. biOasis trades on the OTCQX under the symbol “BIOAF” and on the TSX Venture Exchange under the symbol “BTI”. For more information about the company please visit

Forward Looking Statements

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect” and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: products that we develop may not succeed in preclinical or clinical trials, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward- looking statements and information to reflect subsequent events or circumstances, except as required by law.

On Behalf of the Board of Directors

Rob Hutchison, Chairman & CEO

“Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release”


Scientific: Dr. Reinhard Gabathuler, 1 514-963-6177
General: 778-383-3280 local 101
biOasis Technologies Inc. – [email protected]